For more information, s. Polio ACIP (Advisory Committee on Immunization Practices) Vaccine Recommendations. Preparations Inactivated polio vaccine (IPV) contains a mixture of formalin-inactivated polioviruses types 1, 2 and 3 IPV may contain traces of streptomycin, neomycin, and polymyxin B. The attenuated live oral vaccine is no longer available in the United States because he has caused polio in about 1 out of every 2.4 million people who receive the vaccine. Combination vaccines with IPV, DTaP and sometimes hepatitis B or Hib are also available. Indications IPV is a routine childhood vaccination (see Table: Recommended vaccination schedule for the age of 0-6 years). Routine primary polio vaccination of adults in the US is not recommended. Unimmunized or incompletely immunized adults who may be over exposed to wild poliovirus (eg travelers in endemic areas;. Lab technicians, sample that may contain the poliovirus handle) should be vaccinated with IPV. Fully vaccinated adults who are at increased risk of exposure to poliovirus can receive a booster dose of IPV. Current information on which countries at high risk of polio is believed to be found on the TravelDestinations List of CDC and Polio: Traveler Information. Contraindications and precautions The main contraindication is a severe allergic reaction (eg., Anaphylaxis) after a previous dose or to a vaccine component The most important precaution is Moderate or severe acute febrile illness (the vaccination will be postponed until the disease is over) administration The dose is 0.5 ml in the or s.c. A 4-dose i.m. series is aged 2 months, 4 months, given 6-18 months and 4-6 years. Typically, a combination vaccine for the first 3 immunizations and a single antigen vaccine for the final dose are used. If children aged 4 to 6 years miss a dose of IPV should be given to them as soon as possible a booster. If DTaP-IPV / Hib (Pentacel®) is used for a vaccination course with 4 doses (at the age of 2, 4, 6 and 15 to 18 months), should an additional booster dose of IPV-containing vaccine (IPV or DTaP-IPV [Kinrix®]) are given at age 4 to 6 years, which leads to a dosing regimen with 5 doses; However, DTaP-IPV / Hib should not be used for the booster dose at age 4 to 6 years. The minimum distance 4 to 5 dose should be ? 6 months in order to optimize the response to booster vaccination. A primary series of IPV is recommended for unvaccinated adults at increased risk of exposure to the poliovirus. The recommended distance 1 to 2 dose is 1 to 2 months, the third dose is given 6 to 12 months later. If the protection is needed in 2 to 3 months, 3 doses at an interval of ? 1 month. If it is needed in 1 to 2 months, 2 doses are given at an interval of ? 1 month, and if it is needed in <1 month, 1 dose is given. Side effects with IPV have been associated no side effects. Because the vaccine may contain traces of neomycin, streptomycin and polymyxin B, people who are sensitive to these substances can have an allergic reaction.